Standout Papers

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil... 2005 2026 2012 2019 1.5k
  1. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer (2005)
    William J. Gradishar, Sergei Tjulandin et al. Journal of Clinical Oncology
  2. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer (2011)
    Nicholas J. Robert, Véronique Dièras et al. Journal of Clinical Oncology
  3. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer (2011)
    Joyce O’Shaughnessy, Cynthia Osborne et al. New England Journal of Medicine
  4. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer (2019)
    Aditya Bardia, Ingrid A. Mayer et al. New England Journal of Medicine
  5. Extending Survival with Chemotherapy in Metastatic Breast Cancer (2005)
    Joyce O’Shaughnessy The Oncologist
  6. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer (2017)
    Maura N. Dickler, Sara M. Tolaney et al. Clinical Cancer Research
  7. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024)
    Aditya Bardia, Xichun Hu et al. New England Journal of Medicine
  8. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024)
    Lajos Pusztai, Carsten Denkert et al. Annals of Oncology

Immediate Impact

11 by Nobel laureates 2 from Science/Nature 96 standout
Sub-graph 1 of 16

Citing Papers

Nanomedicine Tumor Targeting
2024 Standout
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
30 intermediate papers

Works of Joyce O’Shaughnessy being referenced

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
2022
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
2019 Standout
and 10 more

Author Peers

Author Last Decade Papers Cites
Joyce O’Shaughnessy 6829 2692 2978 237 9.2k
Sergei Tjulandin 5223 3299 1493 170 8.4k
Chris Twelves 6387 2208 1683 182 9.5k
Olivier Trédan 4285 2340 1697 231 7.5k
Leisha A. Emens 10452 3058 2517 166 14.1k
Carey K. Anders 5242 2683 2498 204 8.3k
Linda T. Vahdat 7383 2015 2673 236 11.2k
Nuhad K. Ibrahim 6209 1726 3866 143 9.8k
Peter Schmid 8002 3424 3134 203 10.6k
Malcolm Ranson 6803 4839 2345 180 11.2k
Mace L. Rothenberg 10811 3469 3368 167 15.0k

All Works

Loading papers...

Rankless by CCL
2026